Observe Medical ASA: First half year 2026 interim report

Oslo, August 25, 2026 - Observe Medical ASA ("the Company" or "Observe Medical") today publishes its financial report for the first half of 2026.

Operating revenues grew 27.4% year-over-year to NOK 14.4 million, driven by increased sales volumes across the UnoMeterT portfolio, while the gross margin improved to 29.5%. The balance sheet was materially strengthened following the 2025 debt restructuring and the wind-down of Biim Ultrasound, lifting the equity ratio from 2.8% to 31.7%.

Highlights - first half 2026 (unaudited, H1 2025 in brackets)

· Operating revenues of NOK 14.4 million (NOK 11.3 million), up 27.4% year -over-year and 92% compared to the second half of 2025 · Adjusted gross result of NOK 4.3 million (NOK 3.0 million), gross margin of

29.5% (+3.3pp)

· Reported EBITDA of NOK 7.9 million (NOK -8.7 million), including a non-cash gain of NOK 18.0 million from the Biim Ultrasound deconsolidation.

· Adjusted EBITDA of NOK -8.3 million, excluding this gain and non-recurring restructuring costs of NOK 2.0 million · Result for the period of NOK 5.6 million (NOK -19.0 million).

"Our global distribution platform is expanding and gaining traction, with an expanding portfolio within the UnoMeterT family, our main priority for the second half is to turn that momentum into sustainable revenue growth.

UnoMeterT SafetiT Max with UnoSafeCoatT technology combines infection prevention, workflow efficiency and sustainability, and is designed to support improved patient outcomes with more efficient use of healthcare resources. These elements are building our position as we aim for commercial and clinical leadership within our category.

Clinically relevant data on our patented UnoSafeCoatT technology has been accepted for publication, solidifying the scientific foundation and commercial credibility for both UnoMeterT SafetiT Max and UnoMeterT Sippi®, our next -generation digital urimeter," says Jørgen Mann, CEO of Observe Medical.

The complete half-year report for 2026 is attached to this announcement and is available at www.observemedical.com.

For further information, please contact:

Jørgen Mann, CEO Observe Medical Mobile: +45 408 67 558

E-mail: jorgen.mann@observemedical.com

Johan Fagerli, CFO Observe Medical Mobile: +47 958 12 765

E-mail: johan.fagerli@observemedical.com

About Observe Medical

Observe Medical is a Nordic medtech company that develops, markets and sells innovative medtech products for the global market. The Company is committed to improving patient welfare and patient outcomes, improving clinical data accuracy and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and commercialization of its broad portfolio of medical technology products, mainly in urine measurement and ultrasound, in combination with targeted M&A and distribution. Observe Medical is working with a network of leading distributors to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available at www.observemedical.com and www.linkedin.com/company/Observe-Medical